The emerging role of immune checkpoint inhibition in malignant lymphoma. - Wikidata - awgldk - TriplyDB

The emerging role of immune checkpoint inhibition in malignant lymphoma.

The emerging role of immune checkpoint inhibition in malignant lymphoma.

http://www.wikidata.org/entity/Q38791036

about

Recent developments in immunotherapy of acute myeloid leukemia.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.Cancer immunotherapy: The dark side of PD-1 receptor inhibition.PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.SOX11 augments BCR signaling to drive MCL-like tumor development.Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival.Evaluation of costimulatory molecules in dogs with B cell high grade lymphoma EBV infection determines the immune hallmarks of plasmablastic lymphoma

P2860

Q38661895-2A7B8781-64B5-4F4B-8DF8-FC4D8C2BB714 Q38818283-DC9A8811-0774-45C2-9930-A7B684A0CDBA Q39237785-90B1FFBA-7C42-4815-B2FB-6203D3628183 Q40040761-D0D1A6F5-6477-4CBE-BDBE-2BAC23471F54 Q47161735-09C08ABA-17AF-4C45-9C69-0C9ADC45F53C Q47397659-3AB74273-171B-4D36-AAA2-69C492086049 Q48517891-10437021-EC81-493E-A5B7-A95631E224CF Q49226138-E381441F-16FA-40F8-BA65-A8B81D6545AD Q49315568-B891FBC2-1486-4474-BEC3-ACA29419EEE4 Q49568952-E7C9C0BD-DAFB-47B0-8A7D-A30FA0D03F1D Q49971148-D1A898DF-791D-40B9-B64B-509C3618B861 Q50056734-43B48307-A66D-4192-837B-8FAA53060A7F Q52609176-91CE00F7-336F-4A5D-B853-BFBB25D27C8C Q52643503-9E36AA76-6529-407E-B6B0-CFAFD5C41EB8 Q55299986-FB7348CE-7707-4223-80BB-2C78535F8FBA Q56890877-97886371-B14E-401C-9D2C-55D511FE37F5 Q56968100-79824B9A-018C-44FE-9ADC-6350E364AED0

P2860

The emerging role of immune checkpoint inhibition in malignant lymphoma.

http://www.wikidata.org/entity/Q38791036

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The emerging role of immune checkpoint inhibition in malignant lymphoma.

@en

type

label

The emerging role of immune checkpoint inhibition in malignant lymphoma.

@en

prefLabel

The emerging role of immune checkpoint inhibition in malignant lymphoma.

@en

P1433

Q38791036-88CCCC13-F099-4440-81FA-A225BC314F73

P1476

Q38791036-B16D3946-F039-40D7-8DFC-36465639A61C

P2093

Q38791036-4284362F-2DBA-46A4-ADB6-6B5213FA546A

Q38791036-76E6C3AB-59FF-4CB3-9CAB-8D1007ECF094

Q38791036-8AAB437E-5498-437A-92FD-1C7F43EA4D98

Q38791036-F71FF0DF-08F6-474D-8CCA-D96A65CEF876

P2860

Q38791036-0388CF77-C179-4724-BF5C-31D6220DAF5A

Q38791036-0965D539-7CA3-4A44-A728-3F87114A5F3E

Q38791036-09830AA0-C17F-4BB7-B7EC-A504D1D035F5

Q38791036-0F6BB40E-E00E-462B-91D4-21329D28E8E3

Q38791036-0F7064B3-2D30-4C59-87DC-56CABE02F54F

Q38791036-0FCEAF69-E110-47FD-BD1E-03D92F85F3EE

Q38791036-10C1AB0E-5B70-420F-A4A4-DDE855CBC3DD

Q38791036-11AB5676-4613-47F0-B747-F7DE82ECE4B0

Q38791036-11ED57CF-150C-4DEB-B636-B15C5469CD80

Q38791036-1452C1FA-1C34-4C48-8472-ABAA33B4C6F4

P304

Q38791036-8684EA86-C2C0-4A62-9079-77CCD3A39C15

P31

Q38791036-9032F114-3525-410E-814C-04930137D67B

P356

Q38791036-7FD5CB60-F878-4050-A6C1-D8710243C74A

P433

Q38791036-BAA7E3DC-BF85-4917-A012-F7C5CEEFBD3A

P478

Q38791036-1CE7FED5-37E5-4E9A-802E-95BBB5C2D48D

P577

Q38791036-0FD2E038-B79C-4E2C-AACA-2D296AEB2550

P698

Q38791036-2F0F4055-988B-4F07-A6D1-6D760EE6F8CC

P932

Q38791036-DC33C16B-472E-464E-A725-F42C06F371C1

P356

HAEMATOL.2016.150656

P1433

P1476

The emerging role of immune checkpoint inhibition in malignant lymphoma.

@en

P2093

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Ida Hude

http://www.w3.org/2001/XMLSchema#string

Paul J Bröckelmann

http://www.w3.org/2001/XMLSchema#string

Stephanie Sasse

http://www.w3.org/2001/XMLSchema#string

P2860

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Molecular and cellular insights into T cell exhaustion

Molecular mechanisms of T cell co-stimulation and co-inhibition

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

PD-1 and its ligands in tolerance and immunity

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

P304

30-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2016.150656

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27884973

http://www.w3.org/2001/XMLSchema#string

P932

5210230

http://www.w3.org/2001/XMLSchema#string